1. Stocks
    2. /
  2. Fisher & Paykel Healthcare Corp Ltd (ASX: FPH)
    3. /

Fisher & Paykel Healthcare Corp Ltd (ASX: FPH) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Fisher & Paykel Healthcare Corp Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $19.67 billion
P/E Ratio 158.34
Dividend Yield 1.16%
Shares Outstanding 583.98 million
Earnings per share 0.226
Dividend per share 0.38
Year To Date Return 61.03%
Earnings Yield 0.63%
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

    • Fisher & Paykel Healthcare Corp Ltd (ASX: FPH)
    Latest News

    Fancy font saying top ten surrounded by gold leaf set against a dark background of glittering stars.
    Share Market News

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    It was a woeful Wednesday for ASX shares today.

    Read more »

    A woman's hand draws a stylised 'Top Ten' on a projected surface.
    Share Market News

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    It was a bloodbath on the ASX boards today...

    Read more »

    Businessman smiles with arms outstretched after receiving good news.
    Share Gainers

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    It was a Monday that Garfield would have been proud of on the ASX today.

    Read more »

    A young woman looks at something on her laptop, wondering what will come next.
    Share Market News

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    It was a tough day to be in the markets this Wednesday.

    Read more »

    A smiling woman with a satisfied look on her face lies on a rug in her home with her laptop open and a large cup on the floor nearby, gazing at the screen. researching new ETFs
    Broker Notes

    6 ASX 300 shares just upgraded by top brokers

    | Sebastian Bowen

    Do you own any of these ASX shares that have just been upgraded to a buy?

    Read more »

    A man in trendy clothing sits on a bench in a shopping mall looking at his phone with interest and a surprised look on his face.
    Share Market News

    5 things to watch on the ASX 200 on Monday

    | James Mickleboro

    Here's what to expect on the ASX 200 on Monday.

    Read more »

    A group of young friends are supposed to be having a rooftop party but the lights have dimmed, the energy is low, and it's a bit of a downer.
    Share Market News

    Here are the top 10 ASX 200 shares today

    | Sebastian Bowen

    It was a horror end to the week for the ASX 200 today.

    Read more »

    Happy woman holding $50 Australian notes
    Dividend Investing

    9 ASX 200 shares trading ex-dividend next week

    | Tristan Harrison

    Distributions are going to be flowing from multiple property businesses.

    Read more »

    A young male investor wearing a white business shirt screams in frustration with his hands grasping his hair after ASX 200 shares fell rapidly today and appear to be heading into a stock market crash
    Share Fallers

    Why Fisher & Paykel, Immutep, Latitude, and Universal Store shares are falling

    | James Mickleboro

    These ASX shares are ending the week in the red...

    Read more »

    A man wearing a white coat and glasses is wide-mouthed in surprise.
    Healthcare Shares

    Here's why this ASX 200 healthcare share is crashing today

    | James Mickleboro

    It has been a tough 12 months for this medical device company.

    Read more »

    woman on the beach in her swimmers holding her surfboard
    52-Week Highs

    Big Wednesday: 12 ASX 200 stocks cracking new 52-week highs

    | Sebastian Bowen

    It's been a cracking day for these 12 ASX 200 shares.

    Read more »

    Two hikers high five each other having climbed to the top pinnacle of the mountain.
    52-Week Highs

    7 ASX 200 stocks smashing new 52-week highs on Monday

    | Sebastian Bowen

    It's been a good day for the ASX 200, but a great one for these seven shares.

    Read more »

    Frequently Asked Questions

    Yes, Fisher & Paykel Healthcare has historically paid two unfranked shareholder dividends a year.

    Fisher & Paykel Healthcare generally pays its shareholder dividends in July and December.

    Yes, Fisher & Paykel Healthcare has a dividend reinvestment plan which allows eligible shareholders in New Zealand, Australia, and the United Kingdom to reinvest all or part of their cash dividends in additional ordinary shares free of brokerage fees.

    Yes, Fisher & Paykel Healthcare Corporation Ltd is listed on the ASX and the New Zealand Exchange.

    Fisher & Paykel Healthcare Corporation Ltd listed on the ASX on 21 November 2001.

    Dividend Payment History Data provided by Morningstar.

    Data provided by Morningstar.
    Ex-Date Amount Franking Type Payable
    26 Jun 2024 $0.2137 0.00% Final 10 Jul 2024
    05 Dec 2023 $0.0318 0.00% Supplemental 18 Dec 2023
    05 Dec 2023 $0.1800 0.00% Interim 18 Dec 2023
    26 Jun 2023 $0.0406 0.00% Supplemental 07 Jul 2023
    26 Jun 2023 $0.2117 0.00% Interim 07 Jul 2023
    08 Dec 2022 $0.0309 0.00% Supplemental 21 Dec 2022
    08 Dec 2022 $0.1645 0.00% Interim 21 Dec 2022
    22 Jun 2022 $0.0397 0.00% Supplemental 06 Jul 2022
    22 Jun 2022 $0.2029 0.00% Final 06 Jul 2022
    02 Dec 2021 $0.0300 0.00% Supplemental 15 Dec 2021
    02 Dec 2021 $0.1784 0.00% Interim 15 Dec 2021
    24 Jun 2021 $0.0388 0.00% Supplemental 07 Jul 2021
    24 Jun 2021 $0.2046 0.00% Final 07 Jul 2021
    03 Dec 2020 $0.0282 0.00% Supplemental 16 Dec 2020
    03 Dec 2020 $0.1510 0.00% Interim 16 Dec 2020
    06 Jul 2020 $0.0274 0.00% Supplemental 17 Jul 2020
    06 Jul 2020 $0.1463 0.00% Final 17 Jul 2020
    06 Dec 2019 $0.0212 0.00% Supplemental 19 Dec 2019
    06 Dec 2019 $0.1148 0.00% Interim 19 Dec 2019
    13 Jun 2019 $0.1287 0.00% Final 05 Jul 2019
    07 Dec 2018 $0.0172 0.00% Supplemental 21 Dec 2018
    07 Dec 2018 $0.0921 0.00% Interim 21 Dec 2018
    21 Jun 2018 $0.0221 0.00% Supplemental 06 Jul 2018
    21 Jun 2018 $0.1151 0.00% Final 06 Jul 2018
    05 Dec 2017 $0.0154 0.00% Supplemental 20 Dec 2017
    05 Dec 2017 $0.7802 0.00% Interim 20 Dec 2017
    15 Jun 2017 $0.0199 0.00% Supplemental 07 Jul 2017
    15 Jun 2017 $0.1074 0.00% Final 07 Jul 2017
    06 Dec 2016 $0.0789 0.00% Interim 21 Dec 2016
    16 Jun 2016 $0.0955 0.00% Final 08 Jul 2016
    09 Dec 2015 $0.0629 0.00% Interim 23 Dec 2015
    17 Jun 2015 $0.0710 0.00% Final 10 Jul 2015
    03 Dec 2014 $0.0537 0.00% Interim 19 Dec 2014
    18 Jun 2014 $0.0650 0.00% Final 04 Jul 2014
    04 Dec 2013 $0.0491 0.00% Interim 19 Dec 2013
    19 Jun 2013 $0.0586 0.00% Final 05 Jul 2013
    29 Nov 2012 $0.0426 0.00% Interim 14 Dec 2012
    20 Jun 2012 $0.0550 0.00% Final 06 Jul 2012
    30 Nov 2011 $0.0413 0.00% Interim 16 Dec 2011
    22 Jun 2011 $0.0534 0.00% Final 08 Jul 2011
    01 Dec 2010 $0.0418 0.00% Interim 17 Dec 2010
    28 Jun 2010 $0.0000 0.00% Final 09 Jul 2010
    10 Dec 2009 $0.0301 0.00% Interim 18 Dec 2009
    22 Jun 2009 $0.0476 0.00% Final 06 Jul 2009
    04 Dec 2008 $0.0095 0.00% Supplemental 12 Dec 2008
    04 Dec 2008 $0.0000 0.00% Interim 12 Dec 2008
    19 Jun 2008 $0.0062 0.00% Supplemental 27 Jun 2008
    19 Jun 2008 $0.0700 0.00% Final 27 Jun 2008
    06 Dec 2007 $0.0095 0.00% Supplemental 14 Dec 2007
    06 Dec 2007 $0.0473 0.00% Interim 14 Dec 2007
    21 Jun 2007 $0.0124 0.00% Supplemental 29 Jun 2007
    21 Jun 2007 $0.0700 0.00% Final 29 Jun 2007
    23 Nov 2006 $0.0095 0.00% Supplemental 01 Dec 2006
    23 Nov 2006 $0.0540 0.00% Interim 01 Dec 2006
    19 Jun 2006 $0.0124 0.00% Supplemental 28 Jun 2006
    19 Jun 2006 $0.0700 0.00% Final 28 Jun 2006
    02 Dec 2005 $0.0095 0.00% Supplemental 09 Dec 2005
    02 Dec 2005 $0.0540 0.00% Interim 09 Dec 2005
    08 Jun 2005 $0.0102 0.00% Supplemental 17 Jun 2005
    08 Jun 2005 $0.0580 0.00% Final 17 Jun 2005
    24 Nov 2004 $0.0088 0.00% Supplemental 03 Dec 2004
    24 Nov 2004 $0.0500 0.00% Interim 03 Dec 2004
    14 Jun 2004 $0.0494 0.00% Supplemental 18 Jun 2004
    14 Jun 2004 $0.2800 0.00% Final 18 Jun 2004

    FPH ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Fisher & Paykel Healthcare Corp Ltd

    Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) is among the world's major designers and manufacturers of respiratory devices. These include products and systems covering in-hospital respiratory care, acute care, and the treatment of obstructive sleep apnea.

    The New Zealand-based company earns around 42% of its revenue from the US market and around 30% in Europe. Its hospital products account for about 65% of its revenue with its at-home sleep apnea devices and other respiratory aids accounting for the rest.

    Fisher & Paykel invests more than 10% of its operating revenue into its own research and development and has thousands of patents and pending applications. The company has manufacturing facilities in both New Zealand and Mexico. 

    FPH Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    20 Nov 2024 $33.56 $-0.70 -2.04% 251,610 $34.23 $34.23 $33.49
    19 Nov 2024 $34.26 $0.07 0.20% 286,381 $34.22 $34.56 $33.93
    18 Nov 2024 $34.19 $0.68 2.03% 374,576 $33.55 $34.35 $33.35
    15 Nov 2024 $33.51 $-0.34 -1.00% 203,744 $34.27 $34.27 $33.31
    14 Nov 2024 $33.85 $-0.10 -0.29% 299,822 $34.01 $34.02 $33.41
    13 Nov 2024 $33.95 $-0.26 -0.76% 281,299 $34.17 $34.25 $33.36
    12 Nov 2024 $34.21 $0.13 0.38% 326,780 $34.08 $34.57 $33.99
    11 Nov 2024 $34.08 $-0.09 -0.26% 172,196 $34.05 $34.27 $33.81
    08 Nov 2024 $34.17 $0.95 2.86% 231,885 $33.47 $34.17 $33.31
    07 Nov 2024 $33.22 $0.27 0.82% 403,716 $32.89 $33.22 $32.35
    06 Nov 2024 $32.95 $-0.05 -0.15% 442,480 $33.33 $33.38 $32.61
    05 Nov 2024 $33.00 $-0.06 -0.18% 223,537 $32.96 $33.31 $32.60
    04 Nov 2024 $33.06 $0.09 0.27% 572,177 $33.00 $33.18 $32.62
    01 Nov 2024 $32.97 $0.16 0.49% 271,604 $32.63 $32.98 $32.21
    31 Oct 2024 $32.81 $0.12 0.37% 464,067 $32.63 $32.92 $32.50
    30 Oct 2024 $32.69 $-0.08 -0.24% 236,248 $32.69 $32.79 $32.21
    29 Oct 2024 $32.77 $-0.96 -2.85% 1,923,765 $33.70 $33.92 $32.77
    28 Oct 2024 $33.73 $0.43 1.29% 139,926 $33.40 $33.86 $33.40
    25 Oct 2024 $33.30 $-0.40 -1.19% 284,760 $33.66 $34.02 $33.30
    24 Oct 2024 $33.70 $0.01 0.03% 336,716 $33.93 $33.93 $33.36
    23 Oct 2024 $33.69 $0.03 0.09% 293,758 $33.48 $33.69 $33.23
    22 Oct 2024 $33.66 $-0.34 -1.00% 469,012 $33.73 $34.16 $33.64

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    12 Sep 2024 Graham McLean Buy 800 $27,932
    As advised by the company. Purchase of Ordinary Shares, As per announcement on 17-09-2024

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Michael Grenfell Daniell Non-Executive Director Nov 2001
    Mr Daniell was General Manager of Fisher & Paykel's medical division from 1990 to 2001 and previously held various technical management and product design roles within the company. Mike is a director of Cochlear Limited, Tait International Limited and the Medical Research Commercialisation Fund. Michael was named a Knight Companion of the New Zealand Order of Merit in June 2021. He is Chair of Quality, Safety & Regulatory Committee.
    Mr Lewis George Gradon Chief Executive OfficerManaging Director Apr 2016
    Mr Gradon spent 15 years as Senior Vice President of Products and Technology, and six years as General Manager of Research and Development. During his 41-year tenure with Fisher & Paykel Healthcare, he has held various engineering positions overseeing the development of our range of products as well the development of manufacturing, quality, intellectual property, supply chain and clinical research functions.
    Mr Neville Mitchell Non-Executive DirectorNon-Executive Chairman Nov 2018
    Mr Mitchell was Chief Financial Officer and Company Secretary of Cochlear between 1995 and 2017. He is a director of Sonic Healthcare and Sigma Healthcare, and is a former director of The Board of Tax, Southeastern Sydney Local Health District, Osprey Medical and Sirtex Medical. Previously, he served on the New South Wales Medical Devices Fund, was Chairman of the Group of 100, and Chairman, Standing Committee (Accounting and Auditing) for the Australian Securities and Investments Commission. He is Chair of Risk Committee and member of Quality, Safety & Regulatory Committee.
    Dr Lisa Margaret McIntyre Non-Executive Director Oct 2021
    Dr McIntyre is a director of The University of Sydney, Studiosity, Nanosonics and Baymatob. She has previously been a director of a range of health entities, including those in healthcare insurance, clinical service delivery and medical research and innovation. Lisa spent 20 years as a senior strategy partner with LEK Consulting providing advice to companies in North America, Asia and Australia. She is member of the Risk Committee.
    Mr Andrew Mark Cross Non-Executive Director Oct 2024
    Mr Cross has governance experience in other listed companies. He currently chairs the board of Chorus, where he has been a director since 2016. He is also a director of Xero, and a board member and Investment Committee Chair of Accident Compensation Corporation (ACC). He is a former chair of Milford Asset Management and a former director of Z Energy, Genesis Energy and Argosy Property. Previously, Mr Cross held executive positions with Deutsche Bank in London and Sydney, as well as Lloyds Corporate Finance/Southpac Corporation in Australia and New Zealand. In those roles, he was an advisor to businesses across a range of sectors including healthcare, utilities, energy, industrials and chemicals.
    Ms Philippa (Pip) Mary Greenwood Non-Executive Director Jun 2017
    Ms Greenwood is the Chair of Westpac New Zealand Limited and also Chair of The a2 Milk Company Limited. Pip was a partner at Russell McVeagh between 2001 and 2019 and served as the firm's Board Chair. She has advised on many corporate transactions. Pip also served as a member of the New Zealand Takeovers Panel from 2007 to 2011. She is member of the Risk Committee.
    Mr Graham McLean Non-Executive Director Oct 2023
    Mr McLean is a director and CEO of CleanSpace Technology and the Chair of Universal Biosensors. Graham previously spent 16 years as an executive at medical device manufacturer Stryker Corporation, most recently as President of the Asia Pacific region situated in Hong Kong and Singapore. Prior to joining Stryker, Graham had finance, audit and commercial positions at Lion Nathan, McVitie's and Unilever. He is member of the Risk Committee.
    Dr Cather Simpson Non-Executive Director Jun 2022
    Dr Simpson is a professor of physics and chemical sciences at the University of Auckland and a partner at Pacific Channel, with expertise in lasers and photonics. She is a director of the International Society for Optics & Photonics (SPIE) and the Dodd-Walls Centre for Photonic & Quantum Technologies, and CEO of Orbis Diagnostics. In 2010, Cather established the Photon Factory at the University of Auckland, from which she co-founded three hard-tech start-ups, including Engender Technologies, where she served as Chief Science Officer from 2011 to 2021. She is Member of Quality, Safety & Regulatory Committee.
    Mr Marcus James Driller Company SecretaryVice President - Corporate
    -
    Ms Raelene Leonard Company Secretary
    -
    Lyndal York Chief Financial Officer
    -
    Andy Niccol Chief Operating Officer
    -
    Raelene Leonard Company Secretary
    -
    Marcus James Driller Company SecretaryVice President - Corporate
    -
    Raelene Leonard General Counsel and Company Secretary
    -
    Malena Ortiz General Director of Mexico Operations
    -
    Desh Edirisuriya General Manager of New Zealand Operations
    -
    Nicholas Fourie Vice President of Information & Communication Technology
    -
    Andrew Somervell Vice President of Products & Technology
    -
    Brian Schultz Vice President of Quality Safety & Regulatory Affairs
    -
    Justin Callahan Vice President of Sales & Marketing
    -
    Jonti Rhodes Vice President of Supply Chain Facilities & Sustainability
    -
    Winston Fong Vice President of Surgical Technologies
    -

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    HSBC Nominees (New Zealand) Limited R601127393 83,534,220 14.30%
    HSBC Nominees (New Zealand) Limited R601127385 51,836,973 8.88%
    JPMorgan Nominees Australia Pty Limited 48,653,179 8.33%
    HSBC Custody Nominees (Australia) Limited 48,028,803 8.22%
    JPMorgan Chase Bank 38,408,220 6.58%
    BNP Paribas Nominees NZ Limited 33,584,164 5.75%
    Citicorp Nominees Pty Limited 28,309,187 4.85%
    Citibank Nominees (Nz) Ltd 28,202,203 4.83%
    Custodial Services Limited 20,719,852 3.55%
    TEA Custodians Limited 19,546,919 3.35%
    New Zealand Superannuation Fund Nominees Limited 16,302,952 2.79%
    Accident Compensation Corporation 9,671,894 1.66%
    Premier Nominees Limited 7,427,317 1.27%
    National Nominees Limited 7,257,801 1.24%
    FNZ Custodians Limited 7,171,404 1.23%
    New Zealand Depository Nominee 6,377,776 1.09%
    JBWere (NZ) Nominees Limited 5,500,973 0.94%
    Public Trust 5,287,041 0.91%
    PT Booster Investments Nominees Limited 4,157,341 0.71%
    New Zealand Permanent Trustees Limited 4,099,423 0.70%

    Profile

    since

    Note